Plans unveiled for Singapore's biologics manufacturing industry

13 December 2014

The Singapore Workforce Development Agency (WDA), Singapore Economic Development Board (EDB) and Biopharmaceutical Manufacturers’ Advisory Council (BMAC) have unveiled a manpower roadmap for the fast-growing biologics manufacturing industry called the Sectoral Manpower Development Plan (SMDP).

The SMDP for the biologics manufacturing industry has been jointly developed by WDA, EDB, and BMAC with the support of industry players including the USA’s AbbVie (NYSE: ABBV), Amgen (Nasdaq: AMGN) and Baxter (NYSE: BAX), the UK’s GlaxoSmithKline (LSE: GSK), and Switzerland’s Lonza, Novartis (NOVN: VX) and Roche (ROG: SIX).

The forward-looking and holistic five-year plan is validated and endorsed by key industry players in the sector. The plan examines the future demand and supply of skilled manpower and available career progression, and recommends a set of strategies covering three main priority areas:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK